Systemic augmentation of αB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Tissue plasminogen activator is the only treatment option for stroke victims; however, it has to be administered within 4.5 h after symptom onset, making its use very limited. This report describes a unique target for effective treatment of stroke, even 12 h after onset, by the administration of αB-crystallin (Cryab), an endogenous immunomodulatory neuroprotectant. In Cryab −/− mice, there was increased lesion size and diminished neurologic function after stroke compared with wild-type mice. Increased plasma Cryab was detected after experimental stroke in mice and after stroke in human patients. Administration of Cryab even 12 h after experimental stroke reduced both stroke volume and inflammatory cytokines associated with stroke pathology. Cryab is an endogenous anti-inflammatory and neuroprotectant molecule produced after stroke, whose beneficial properties can be augmented when administered therapeutically after stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
Temporal and Spatial Dynamics of Cerebral Immune Cell Accumulation in Stroke
Gelderblom, M., Leypoldt, F., Steinbach, K., Behrens, D., Choe, C.-U., Siler, D. A., Arumugam, T. V., Orthey, E., Gerloff, C., Tolosa, E., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.534503 · Cited by 1,066 · cited 1×
“2A), consistent with other reports (16).”
Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke
Clarkson, A. N., Huang, B. S., MacIsaac, S. E., Mody, I., & Carmichael, S. T. (2010) · Nature · doi:10.1038/nature09511 · Cited by 869 · cited 2×
“In stroke, GABA modulation beginning 3 d after stroke promoted functional recovery but did not influence the size of the stroke (43), in contrast to the current results with Cryab, where stroke size was reduced when the treatment was started even 12 h after the stroke.”
BackgroundResultShichita, T., Sugiyama, Y., Ooboshi, H., Sugimori, H., Nakagawa, R., Takada, I., Iwaki, T., Okada, Y., Iida, M., Cua, D. J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1999 · Cited by 842
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001) · Science · doi:10.1126/science.1062960 · Cited by 829 · cited 1×
“Cryab is the most abundant induced transcript in multiple sclerosis (MS) lesions, and is highly expressed in areas of inflammation (9).”
BackgroundSelf-citationA new penumbra: transitioning from injury into repair after stroke
Lo, E. H. (2008) · Nature Medicine · doi:10.1038/nm1735 · Cited by 611 · cited 1×
“Some proposed targets for therapy of stroke have dual roles, causing deleterious effects initially and becoming beneficial later on (45).”
BackgroundInhibitory role for GABA in autoimmune inflammation
Bhat, R., Axtell, R., Mitra, A., Miranda, M., Lock, C., Tsien, R. W., & Steinman, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915139107 · Cited by 509 · cited 1×
“agonists could suppress CNS inflammation in vivo (44).”
BackgroundSelf-citationPathophysiology and therapy of experimental stroke
Hossmann, K.-A. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9008-1 · Cited by 475
Cited by
Knowland, D., Arac, A., Sekiguchi, K. J., Hsu, M., Lutz, S. E., Perrino, J., Steinberg, G. K., Barres, B. A., Nimmerjahn, A., & Agalliu, D. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.003 · Cited by 703
“We subjected 8–20 week-old transgenic mice to t-MCAO for 45 min (Arac et al., 2011), then imaged changes in endothelial TJ strands and leakage of tracers across the damaged barrier, in 120–240 μm thick cortical volumes within the stroke core area during a 6–58 h time period post-t-MCAO (Figure 2A–”
Self-citationSmall heat shock proteins: Role in cellular functions and pathology
Bakthisaran, R., Tangirala, R., & Rao, C. M. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.12.019 · Cited by 459
Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments
George, P. M., & Steinberg, G. K. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.041 · Cited by 393
Self-citationB-Lymphocyte-Mediated Delayed Cognitive Impairment following Stroke
Doyle, K. P., Quach, L. N., Solé, M., Axtell, R. C., Nguyen, T.-V. V., Soler-Llavina, G. J., Jurado, S., Han, J., Steinman, L., Longo, F. M., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4098-14.2015 · Cited by 339
Self-citationImmunology of Relapse and Remission in Multiple Sclerosis
Steinman, L. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120227 · Cited by 330
Self-citation
Metadata
- Authors
- Arac, A., Brownell, S. E., Rothbard, J. B., Chen, C., Ko, R. M., Pereira, M. P., Albers, G. W., Steinman, L., & Steinberg, G. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-07-26
- Volume
- 108
- Issue
- 32
- Pages
- 13287-13292
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1974848503
- Cited by
- 141
- References
- 8
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic augmentation of αB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. https://app.cochat.ai/papers/10.1073/pnas.1107368108
- The paper
- Arac, A., Brownell, S. E., Rothbard, J. B., Chen, C., Ko, R. M., Pereira, M. P., Albers, G. W., Steinman, L., & Steinberg, G. K. (2011). Systemic augmentation of αB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1107368108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.